| 主权项 |
1. A method of treating lung cancer in a human by administering an effective amount of a compound of formula (I),including a stereochemically isomeric form thereof;
wherein Y is CH2 or CH2—CH2; R1 is aryl or Het;
wherein aryl is phenyl or naphthalenyl;wherein Het is thienyl, pyrrolyl, pyrrolinyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, tetrazolyl, thiadiazolyl, furanyl, piperidinyl, pyridinyl, pyridazinyl, pyrimidinyl, piperazinyl, pyrazinyl, triazinyl, indolizinyl, azaindolizinyl, indolyl, indolinyl, benzothienyl, indazolyl, benzoxazolyl, benzimidazolyl, benzofuranyl, benzothiazolyl, benzotriazolyl, chromanyl, purinyl, quinolinyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxazolinyl, naphthyridinyl or pteridinyl; each aryl or Het can be substituted with one or two substituents each independently selected from halo, cyano, nitro, hydroxycarbonyl, C1-6alkyl, C1-6alkyloxycarbonyl, C1-6alkylNR8R9, and —OR8 or R1 is a radical of formula wherein X1 is CH2, NH or N—CH3; wherein X2 is CH2, C═O, O, NH or N—CH3; wherein R10 is phenyl, pyridinyl, pyridazinyl or pyrimidinyl, wherein each phenyl, pyridinyl, pyridazinyl or pyrimidinyl can be substituted with one or two substituents each independently selected from halo, hydroxy, cyano, C1-6alkyl, amino, polyhaloC1-6alkyl or C1-6alkyloxy; or R1 is a radical of formula wherein X3 is CH or N; R2 is methyl, ethyl, propyl or C3-6cycloalkyl; each R3 and R4 is hydrogen; each R5, R6, and R7 is hydrogen; each R8 and R9 is independently selected from hydrogen, halo, C1-6alkyl, or a N-oxide form thereof or a pharmaceutically acceptable addition salt thereof. |
